CAMP4 Therapeutics (NASDAQ:CAMP) Raised to Strong-Buy at Chardan Capital

CAMP4 Therapeutics (NASDAQ:CAMP) was upgraded by equities research analysts at Chardan Capital to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports.

Other equities analysts also recently issued reports about the company. Cantor Fitzgerald restated an “overweight” rating on shares of CAMP4 Therapeutics in a report on Friday, March 6th. Weiss Ratings downgraded CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 21st. Leerink Partners raised their price objective on CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an “outperform” rating in a report on Thursday, April 2nd. Finally, Rodman & Renshaw began coverage on CAMP4 Therapeutics in a report on Tuesday, April 14th. They issued a “buy” rating and a $7.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, CAMP4 Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $8.25.

CAMP4 Therapeutics Trading Up 8.2%

NASDAQ CAMP opened at $4.34 on Wednesday. The business’s 50-day moving average price is $4.37 and its 200 day moving average price is $4.68. CAMP4 Therapeutics has a twelve month low of $1.30 and a twelve month high of $7.75. The company has a market capitalization of $225.38 million, a PE ratio of -1.84 and a beta of 0.08.

CAMP4 Therapeutics (NASDAQ:CAMP) last released its earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.11). The business had revenue of $1.29 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 194.74% and a negative net margin of 2,193.72%. Equities analysts predict that CAMP4 Therapeutics will post -0.82 EPS for the current year.

Institutional Investors Weigh In On CAMP4 Therapeutics

Large investors have recently modified their holdings of the stock. Bridgeway Capital Management LLC acquired a new stake in shares of CAMP4 Therapeutics in the second quarter valued at about $36,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of CAMP4 Therapeutics in the fourth quarter valued at about $61,000. Jefferies Financial Group Inc. acquired a new stake in shares of CAMP4 Therapeutics in the fourth quarter valued at about $70,000. Bank of America Corp DE acquired a new stake in shares of CAMP4 Therapeutics in the fourth quarter valued at about $86,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of CAMP4 Therapeutics in the fourth quarter valued at about $115,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.